TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
AVLN

Avalyn Pharma Inc.

Healthcare · Biotechnology

28.40$ +1.0% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Avalyn Pharma Inc. (AVLN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.8% of the shares are freely tradable; institutional investors hold 66.0%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 66.0%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 61.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.4%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 44Mio.

Largest Shareholders

Institutions

Institutions AVLN
Name Stake (%) Shares Change (%) Date
SR ONE CAPITAL MANAGEMENT, LP 7.46 3,308,649 +0.0 06/30/2026
Perceptive Advisors LLC 6.03 2,675,296 +0.0 06/30/2026
NVP Associates LLC 5.12 2,268,404 +0.0 06/30/2026
Wellington Management Company LLP 4.97 2,201,986 +0.0 06/30/2026
Catalio Capital Management, LP 3.78 1,675,830 +0.0 06/30/2026
Eventide Asset Management, LLC 3.10 1,375,486 +0.0 06/30/2026
Pivotal bioVenture Partners Investment Advisor LLC 2.18 966,792 +0.0 06/30/2026
Citadel Advisors Llc 2.16 959,098 +0.0 06/30/2026

Funds

Funds AVLN
Name Stake (%) Shares Change (%) Date
Eventide Healthcare & Life Sciences I 3.10 1,375,486 -93.3 06/30/2026
Fidelity Small Cap Growth 2.78 1,231,620 +1.2 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?